Richard M. Toselli - 17 Nov 2022 Form 4 Insider Report for INVIVO THERAPEUTICS HOLDINGS CORP.

Role
CEO and CMO, Director
Signature
/s/ Heather Hamel, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
17 Nov 2022
Net transactions value
$0
Form type
4
Filing time
21 Nov 2022, 16:04:49 UTC
Previous filing
23 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVIV Stock Option (right to buy) Award $0 +61,000 $0.000000 61,000 17 Nov 2022 Common Stock 61,000 $2.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on November 17, 2022. The shares underlying the option vest over two years, with 50% of the shares vesting on November 17, 2023 and the remaining shares vesting on November 17, 2024.